SUBSCRIBE
SUBSCRIBE

Kaylei Whalen

Rita Levi-Montalcini, winner of the 1986 Nobel Pri
Business
Masters in Memoriam: Celebrating Rita Levi-Montalcini
Rita Levi-Montalcini is perhaps best known for her award-winning work in the discovery and isolation of Nerve Growth Factor (NGF) in 1956. Here’s more about her.
April 24, 2022
 · 
5 min read
 · 
Kaylei Whalen
Pierre Suu/Getty Images
Exploring the Therapeutic Potential of Protective Genetic Variations
Genetic varations within the human genome is littered with breadcrumbs leading right up to new therapeutic possibilities.
April 19, 2022
 · 
5 min read
 · 
Kaylei Whalen
Drug Development
More Unique Therapeutic Possibilities Posed by Rare Human Genes
The discovery of a unique, inheritable resistance to Ebola infection has inspired the development of therapeutics that may not only be effective against Ebola but against COVID-19, as well.
March 11, 2022
 · 
5 min read
 · 
Kaylei Whalen
Report: Global Psoriatic Arthritis Market Could Exceed $13B by 2026
The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.
March 10, 2022
 · 
2 min read
 · 
Kaylei Whalen
Pictured: BioNTech flags fly in the wind/Andreas A
Drug Development
BioNTech and Regeneron Turn Attention to NSCLC in Partnership Expansion
BioNTech announced an expansion on its collaboration with Regeneron to continue advancing mRNA technology and develop novel treatments for a variety of cancers.
March 9, 2022
 · 
2 min read
 · 
Kaylei Whalen
Drug Development
The Unique Therapeutic Possibilities Posed by Rare Human Genes
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.
February 7, 2022
 · 
4 min read
 · 
Kaylei Whalen
Policy
Impostors! Crime in the Time of COVID-19 Targets Life Science Industry
While many of these scams targeted the public at large, scammers also turned their sights to those sources that would naturally be on the spot as the result of demand.
January 17, 2022
 · 
5 min read
 · 
Kaylei Whalen
Dr Beatrice Mintz
Business
Cancer Research Legend Beatrice Mintz Gone at 100
Beatrice Mintz, the research legend passed away at the age of 100. Her contribution to the field is unforgettable. ere’s more about her and the research.
January 14, 2022
 · 
2 min read
 · 
Kaylei Whalen
courtesy of Shutterstock
Drug Development
Atai Gets Greenlight to Proceed with Treatment Resistant Depression Asset
PCN-101 was recently awarded Investigational New Drug (IND) status by the U.S. Food and Drug Administration. It’s a for treating the patients with treatment resistant depression.
January 12, 2022
 · 
2 min read
 · 
Kaylei Whalen
Drug Development
Beyond COVID-19: the Potential of mRNA in Occupational Cancer
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
January 12, 2022
 · 
5 min read
 · 
Kaylei Whalen
Business
Gameto Nets $20M on Path to Redefining Reproductive Longevity
Gameto has created a three-part platform for ovarian therapeutics that will address menopause and assisted fertility.
January 11, 2022
 · 
2 min read
 · 
Kaylei Whalen
Business
Maze Therapeutics Nets $190M to Propel Precision Medicine Programs
The company has produced a varied pipeline focused on the development of precision pharmacological treatments for nine different programs.
January 10, 2022
 · 
2 min read
 · 
Kaylei Whalen
Deals
Cell Tech Stock to Go Public in 2022 Thanks to Senti/Dynamics Merger
Pioneers of synthetic biology have rallied together under the development of Senti Biosciences Inc, co-founded and led by Timothy Lu, associate professor of biological engineering, electrical engineering, and computer science at the Massachusetts Institute of Technology.
December 21, 2021
 · 
2 min read
 · 
Kaylei Whalen
Kymera’s First R&D Day Highlights Clinical Success and Reveals 5-Year Plan
In addition to showcasing data from their in-progress Phase I clinical trial, Kymera Therapeutics also announced their newest development program and outlined the company’s 5-year plan in their very first R&D Day.
December 17, 2021
 · 
2 min read
 · 
Kaylei Whalen
Drug Development
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
December 16, 2021
 · 
7 min read
 · 
Kaylei Whalen
Load More